The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation
Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
100
Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
Equal volume normal saline substitute for dexmedetomidine
No.24 Fukang Road,Nankai District
Tianjin, Tianjin Municipality, China
RECRUITINGPeri-operative mortality
Time frame: through study completion, an average of 5 weeks
The incidence of cardiac complications
Time frame: from anesthesia induction to 24 hours after operation
Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence
myohemoglobin,creatine kinase isoenzyme,cardiac troponinⅠ,Heart-type fatty acid-binding protein
Time frame: before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.